VIBRAMYCIN Oral Suspension Gets FDA Safety Seal of Approval
Published Date: 4/9/2025
Notice
Summary
The FDA says VIBRAMYCIN oral suspension (25 mg/5 mL) wasn’t pulled from the market because of safety or effectiveness problems. This means generic versions can keep getting approved, so patients and pharmacies won’t face shortages or price hikes. If you rely on this medicine, good news—it’s here to stay!
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
Generic Approvals Continue for VIBRAMYCIN
The FDA determined that VIBRAMYCIN (doxycycline) oral suspension, equivalent 25 mg base/5 mL, was not withdrawn from sale for reasons of safety or effectiveness. Because of that determination, the FDA will not begin procedures to withdraw approvals of abbreviated new drug applications (ANDAs) that refer to this product and can continue to approve ANDAs that refer to it if they meet legal and regulatory requirements.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20085, Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Voluntary Improvement Program
The FDA is asking for public feedback by November 2, 2026, on its Voluntary Improvement Program (VIP), which helps medical device makers improve quality through third-party reviews. This program supports better products and safer devices without adding extra costs or deadlines for companies. It’s all about encouraging excellence and teamwork between the FDA, industry, and partners like the Medical Device Innovation Consortium.
Previous / Next Documents
Previous: 2025-06052, Teva Pharmaceuticals USA, Inc., et al.; Withdrawal of Approval of 23 Abbreviated New Drug Applications; Correction
The FDA fixed a mistake about pulling approvals for 23 generic drug applications. One company, Breckenridge Pharmaceutical, asked to keep their approval for a migraine drug, and the FDA agreed. So, while most approvals end on February 14, 2025, Breckenridge’s drug stays approved, keeping things clear and fair for everyone involved.
Next: 2025-06057, Foreign-Trade Zone (FTZ) 50, Notification of Proposed Production Activity; Logitech; (Audio, Visual, and Gaming Equipment); Ontario, California
Logitech wants to start making cool audio, video, and gaming gear at its Ontario, California facility inside Foreign-Trade Zone 50. This move could save them money on import duties for certain parts, helping them build things like headsets, webcams, and sim racing gear more cheaply. The public can share their thoughts until May 19, 2025, so don’t miss your chance to weigh in!